The document provides an overview of South Africa and its pharmaceutical market from the perspective of Pharmaplan Pty Ltd, a South African pharmaceutical company. It summarizes that South Africa has a growing economy and pharmaceutical market but also faces challenges like unemployment, crime, and healthcare issues like HIV/AIDS. Pharmaplan has experienced exceptional organic growth over 12 years, focuses on specialty pharmaceuticals and hospitals, and is interested in partnering with other niche-focused companies to continue expanding in South Africa and the greater SADC region.
9. 7 Key market features against other major emerging markets * Average from 01/01/08 until 04/11/08 Source: CIA World Factbook, The Economist Intelligent Unit, Standard Bank Group Economics, Credit Suisse
10.
11. The largest contributor to GDP is the services sector, comprising finance, insurance, real estate and business services
12. The South African Reserve Bank (SARB) has increased interest rates six times since the beginning of 2007, driven by monetary policy which targets an inflation band of 3% to 6%
13. Economic activity is experiencing a slowdown (in midst of global markets and domestic issues) following unprecedented growth over the past several years
14. As result of higher monetary policy and credit-lending criteria, household demand has decreased (following a period of easy access to credit in recent times)
15. With a large measure of macro stability achieved, the aim of economic policy is to lower unemployment and poverty through raising the growth potential of the economy
17. Significant infrastructure capital expenditure is planned from 2008 enabling an improvement in real GDP growth ahead of the World Cup in 2010Prime lending rates Average annual CPI Source: Standard Bank Research Economics Macro-Economic Forecast
51. 16 SA Demographics 8 m lives insured (Private) 16 m lives employed, not insured (Emerging Market – MHC) 26 m lives not employed, not insured (Public Healthcare)
65. 19 Pharmaplan Vision To be South Africa's Premier Specialist Pharmaceutical Company "There are currently 12 specialist driven products in the top 30 and 17 in the top 50" Scrip '05
66. 20 But … RSA also needs - Representation of Top NICHE generic suppliers in South(ern) Africa “It is therefore very crucial for us to ensure that access to affordable, safe, effective and quality drugs is established” Dr. MantoTshabalala Msimang, Minister of Health, Keynote address, 10 September 2001
67.
68. Complemented by "niche" generic suppliers“Provide new therapeutic entities by making financial headroom resulting from generic substitution of out-of-patent products”